APL

ANALYSIS OF PML/RARA ONCOGENIC COMPLEX IN ACUTE PROMYELOCYTIC LEUKEMIA

Coordinatore	UNIVERSITE PARIS DIDEROT - PARIS 7    more  Organization address address: RUE THOMAS MANN 5 city: PARIS postcode: 75205 contact info Titolo: Ms. Nome: Muriel Cognome: Maurice Email: send email Telefono: +33 1 57 27 55 48 Fax: +33 1 57 27 55 47
Nazionalità Coordinatore	France [FR]
Totale costo	166˙145 €
EC contributo	166˙145 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IEF
Funding Scheme	MC-IEF
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-11-01   -   2012-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITE PARIS DIDEROT - PARIS 7  Organization address address: RUE THOMAS MANN 5 city: PARIS postcode: 75205 contact info Titolo: Ms. Nome: Muriel Cognome: Maurice Email: send email Telefono: +33 1 57 27 55 48 Fax: +33 1 57 27 55 47	FR (PARIS)	coordinator	166˙145.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Acute promyelocytic leukemia (APL) appears to be primarily a monogenic disease characterised by a specific t(15 ;17) translocation that fuses the PML and the RARA gene to generate a PML/RAR fusion protein. PML/RARA is a transcriptional repressor, and RARA homo-dimerisation through the coiled coil of PML was believed to be the basis for repression via enhanced binding of co-repressors. Clinically, APL is exquisitely sensitive to retinoic acid (RA), arsenic trioxide and cAMP. This cardinal feature of the disease has been used to model its pathogenesis by analyzing the response to therapy of primary cells in vivo and ex vivo. Our aim is a further understanding the pathogenesis of acute promyelocytic leukemia, in particular the molecular bases of its response to RA, arsenic and cAMP. This will be essentially achieved through the analysis of the phenotype and transcriptome of cells or animals expressing PML/RARA mutants, by applying innovative approaches in cellular and molecular biology, such as purification of tagged proteins and ChIP. We propose two main objectives: - Partners identification of the oncogenic PML/RARA complex. Subsequently, we will analyse the functional domains of the complex and the changes in the complex induced by RA, arsenic and cAMP. - Analysis of PML/RARA-dependent target gene repression. We will compare between different PML/RARA mutants in respect to the chromatin or DNA status of the target gene promoters. This project addresses new therapeutic targets in APL and other types of cancer where RARA is implicated. It is a multidisciplinary project that involves a highly valuable education for the candidate in new scientific aspects related to her research field.'